


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (Currently Amended) A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



wherein

R<sub>1</sub> and R<sub>3</sub> independently represent H; F; Cl; Br; -NO<sub>2</sub>; -CN; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by F or Cl; or C<sub>1</sub>-C<sub>6</sub> alkoxy optionally substituted by F;

R<sub>2</sub> represents H, or optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or -N(R<sub>5</sub>)- wherein R<sub>5</sub> represents H or C<sub>1</sub>-C<sub>6</sub> alkyl;

X represents a bond or a divalent C<sub>1</sub>-C<sub>6</sub> alkylene radical;

R<sub>4</sub> represents -C(=O)NR<sub>6</sub>R<sub>7</sub>, -NR<sub>7</sub>C(=O)R<sub>6</sub>, -NR<sub>7</sub>C(=O)OR<sub>6</sub>, -NHC(=O)NHR<sub>6</sub> or -NHC(=S)NHR<sub>6</sub> wherein

R<sub>6</sub> represents H, or a radical of formula -(Alk)<sub>b</sub>-Q wherein b is 0 or 1 and

Alk is an optionally substituted divalent straight chain or branched C<sub>1</sub>-C<sub>12</sub> alkylene, C<sub>2</sub>-C<sub>12</sub> alkenylene or C<sub>2</sub>-C<sub>12</sub> alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R<sub>8</sub>)- radicals wherein R<sub>8</sub> represents H or C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> alkenyl, C<sub>3</sub>-C<sub>4</sub> alkynyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and

Q represents H; -CF<sub>3</sub>; -OH; -SH; -NR<sub>8</sub>R<sub>8</sub> wherein each R<sub>8</sub> may be the same or different; an ester group; or an optionally substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>5</sub>-C<sub>7</sub> cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R<sub>7</sub> represents H or C<sub>1</sub>-C<sub>6</sub> alkyl; or when taken together with the atom or atoms to which they are attached R<sub>6</sub> and R<sub>7</sub> form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms;

provided that when R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are all H, Y is -NH-, and X represents a bond, then R<sub>4</sub> may not be -C(=O)NR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are H, or -NHC(=O)NHR<sub>6</sub>, wherein R<sub>6</sub> is -(Alk)<sub>b</sub>-Q wherein b is 1, Alk is C<sub>1</sub> alkylene and Q is H.

Claim 2. (Original) A compound as claimed in claim 1 wherein R<sub>1</sub> is H, F, Cl, methyl or methoxy.

Claim 3. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>2</sub> is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

Claim 4. (Currently Amended) A compound as claimed in claim 1 wherein R<sub>3</sub> is H, F, Cl, methyl, or methoxy, ~~or methylenedioxy~~.

Claim 5. (Previously Presented) A compound as claimed in claim 1 wherein Y is -O-, -S-, or -N(R<sub>5</sub>)- wherein R<sub>5</sub> represents H or methyl.

Claim 6. (Previously Presented) A compound as claimed in claim 1 wherein X is a bond, or a -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>- radical.

Claim 7. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>4</sub> represents -C(=O)NHR<sub>6</sub>, -NR<sub>7</sub>C(=O)R<sub>6</sub>, -NR<sub>7</sub>C(=O)OR<sub>6</sub>, -NHC(=O)NHR<sub>6</sub> or -NHC(=S)NHR<sub>6</sub> and in these R<sub>6</sub> is H or a radical of formula -Alk<sub>b</sub>-Q wherein b is 0 or 1 and

Alk is a -(CH<sub>2</sub>)<sub>n</sub>-, -CH((CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>)(CH<sub>2</sub>)<sub>n</sub>-,  
-CH((CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>p</sub>CH<sub>3</sub>)(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-,

or  $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$ , radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, -OH, -COOCH<sub>3</sub> phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl-, and

R<sub>7</sub> is H, or when taken together with the nitrogen atom to which they are attached R<sub>6</sub> and R<sub>7</sub> form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

Claim 8. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>1</sub> is H, F, or Cl; R<sub>2</sub> is H; R<sub>3</sub> is H, F, or Cl; Y is -NH-; X is a bond; and R<sub>4</sub> represents  $-C(=O)NHR_6$ ,  $-NR_7C(=O)R_6$ ,  $-NR_7C(=O)OR_6$  or  $-NHC(=O)NHR_6$  wherein:

R<sub>6</sub> is H or a radical of formula  $-Alk_b-Q$  wherein

b is 0 or 1 and

Alk is a  $-(CH_2)_n-$ ,  $-CH((CH_2)_mCH_3)(CH_2)_n-$ ,  $-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_m-$ , or  $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$ , radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, -OH, -COOCH<sub>3</sub> phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl-, and

R<sub>7</sub> is H, or when taken together with the nitrogen atom to which they are attached R<sub>6</sub> and R<sub>7</sub> form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.


Claim 9. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>1</sub> is F, R<sub>2</sub> is H or cyclopropyl, R<sub>3</sub> is H, X is a bond, and R<sub>4</sub> is  $-C(=O)NHR_6$ ,  $-NRHC(=O)R_6$ , or  $-NHC(=O)NHR_6$ .

Claim 10. (Original) N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide, or pharmaceutically or veterinarily acceptable salt thereof.

Claim 11. (Canceled)

Claim 12. (Canceled)

Claim 13. (Currently Amended) A method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound ~~as claimed in claim 1~~ of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



wherein

R<sub>1</sub> and R<sub>3</sub> independently represent H; F; Cl; Br; -NO<sub>2</sub>; -CN; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by F or Cl; or C<sub>1</sub>-C<sub>6</sub> alkoxy optionally substituted by F;

R<sub>2</sub> represents H, or optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or -N(R<sub>5</sub>)- wherein R<sub>5</sub> represents H or C<sub>1</sub>-C<sub>6</sub> alkyl;

X represents a bond or a divalent C<sub>1</sub>-C<sub>6</sub> alkylene radical;

R<sub>4</sub> represents -C(=O)NR<sub>6</sub>R<sub>7</sub>, -NR<sub>7</sub>C(=O)R<sub>6</sub>, -NR<sub>7</sub>C(=O)OR<sub>6</sub>, -NHC(=O)NHR<sub>6</sub> or -NHC(=S)NHR<sub>6</sub> wherein

R<sub>6</sub> represents H, or a radical of formula -(Alk)<sub>b</sub>-Q wherein b is 0 or 1 and

Alk is an optionally substituted divalent straight chain or branched C<sub>1</sub>-C<sub>12</sub> alkylene, C<sub>2</sub>-C<sub>12</sub> alkenylene or C<sub>2</sub>-C<sub>12</sub> alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R<sub>8</sub>)- radicals wherein R<sub>8</sub> represents H or C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> alkenyl, C<sub>3</sub>-C<sub>4</sub> alkynyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and

Q represents H; -CF<sub>3</sub>; -OH; -SH; -NR<sub>8</sub>R<sub>8</sub> wherein each R<sub>8</sub> may be the same or different; an ester group; or an optionally substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>5</sub>-C<sub>7</sub> cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R<sub>7</sub> represents H or C<sub>1</sub>-C<sub>6</sub> alkyl; or when taken together with the atom or atoms to which they are attached R<sub>6</sub> and R<sub>7</sub> form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms.

Claim 14. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as claimed in claim 1 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Claim 15. (Previously Presented) A compound as claimed in claim 2 wherein R<sub>2</sub> is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

Claim 16. (Currently Amended) A compound as claimed in claim 2 wherein R<sub>3</sub> is H, F, Cl, methyl, or methoxy, ~~or methylenedioxy~~.

Claim 17. (Currently Amended) A compound as claimed in claim 3 wherein R<sub>3</sub> is H, F, Cl, methyl, or methoxy, ~~or methylenedioxy~~.

Claim 18. (Currently Amended) A compound as claimed in claim 15 wherein R<sub>3</sub> is H, F, Cl, methyl, or methoxy, ~~or methylenedioxy~~.

Claim 19. (Previously Presented) A compound as claimed in claim 2 wherein Y is -O-, -S-, or -N(R<sub>5</sub>)- wherein R<sub>5</sub> represents H or methyl.

Claim 20. (Previously Presented) A compound as claimed in claim 2 wherein X is a bond, or a -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>- radical.

Claim 21. (Previously Presented) A compound as claimed in claim 2 wherein R<sub>4</sub> represents -C(=O)NHR<sub>6</sub>, -NR<sub>7</sub>C(=O)R<sub>6</sub>, -NR<sub>7</sub>C(=O)OR<sub>6</sub>, -NHC(=O)NHR<sub>6</sub> or -NHC(=S)NHR<sub>6</sub> and in these R<sub>6</sub> is H or a radical of formula -Alk<sub>b</sub>-Q wherein  
b is 0 or 1 and  
Alk is a -(CH<sub>2</sub>)<sub>n</sub>-, -CH((CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>)(CH<sub>2</sub>)<sub>n</sub>-,

$-\text{CH}((\text{CH}_2)_m\text{CH}_3)((\text{CH}_2)_p\text{CH}_3)(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_m-$ ,  
or  $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_m-$ , radical where n is 1, 2, 3 or 4 and m and p are  
independently 0, 1, 2, 3 or 4, and Q represents H, -OH, -COOCH<sub>3</sub> phenyl, cyclopropyl,  
cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl, and

R<sub>7</sub> is H, or when taken together with the nitrogen atom to which they are attached R<sub>6</sub>  
and R<sub>7</sub> form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

Claim 22. (Previously Presented) A method of immunomodulation in humans and  
non-human primates, comprising administration to a subject in need of such treatment an  
immunomodulatory effective dose of a compound as claimed in claim 2.

Claim 23. (Previously Presented) A method of immunomodulation in humans and  
non-human primates, comprising administration to a subject in need of such treatment an  
immunomodulatory effective dose of a compound as claimed in claim 3.

Claim 24. (Previously Presented) A pharmaceutical or veterinary composition com-  
prising a compound as claimed in claim 2 together with a pharmaceutically or veterinarily  
acceptable excipient or carrier.

Claim 25. (Previously Presented) A pharmaceutical or veterinary composition com-  
prising a compound as claimed in claim 3 together with a pharmaceutically or veterinarily  
acceptable excipient or carrier.